Zepbound Alternatives & Comparison
Zepbound (tirzepatide) set beside Wegovy, Mounjaro, Saxenda: how each works, what its trials measured, what it costs, and who sells it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Zepbound Alternatives Compared
Approved for the same weight-management use, but acts on GLP-1 alone rather than GIP and GLP-1 together
Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
One head-to-head settles the weight question and does not settle the whole question. SURMOUNT-5 put Zepbound at −20.2% against Wegovy's −13.7% at 72 weeks, a 6.5-point gap under one protocol. Wegovy answers a different question: SELECT cut major cardiovascular events 20%, and Zepbound's SURPASS-CVOT does not read out until 2027. Cash pricing is a wash at $349–$499. So the honest split is magnitude of weight loss against proven event reduction — and that is a prescriber's call, not a table's.
Full Wegovy vs Zepbound comparison →Tirzepatide again, carrying a type 2 diabetes approval instead of a weight-management one
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon.
One molecule, one dose ladder, one maker, sold twice under two names. Diabetes sits on the Mounjaro label; obesity and sleep apnea sit on Zepbound's. Pricing is identical at $349 starter and $499 maintenance for vials. The practical difference is which label your prescription is written against, because that is what decides coverage. Nothing pharmacological separates them, and any page implying otherwise is selling something.
Full Mounjaro vs Zepbound comparison →Trades weight loss for history: a daily injection that has been in use far longer
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours.
A daily liraglutide injection against a weekly dual agonist, and there is not much contest on either axis a buyer cares about. Zepbound runs $349–$499 through LillyDirect. Saxenda has no cash-pay tier of its own and lists near $1,400. Saxenda's residual argument is availability — it has been on the market since 2014 and is sometimes covered where newer drugs are excluded, which is a formulary fact rather than a clinical one.
Full Saxenda vs Zepbound comparison →A daily pill rather than an injection, still working through the incretin pathway
Orforglipron is not built as a peptide. It is a small organic molecule that binds the GLP-1 receptor and switches it on directly.
The strongest injectable against the first non-peptide pill. SURMOUNT-1 reported −20.9% at 72 weeks for Zepbound; ATTAIN-1 reported −11.1% at 72 weeks for Foundayo — different trials, but both at 72 weeks in obesity, which makes the comparison unusually readable for a cross-trial one. Neither has published cardiovascular outcomes. Zepbound is $349–$499 through LillyDirect; Foundayo's direct-pay tier is still rolling out. Roughly: more weight loss, or no needle and no cold chain.
Full Foundayo vs Zepbound comparison →Sits outside the GLP-1 class entirely, which matters if incretin GI effects are the problem
Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect.
SURMOUNT-1 reported −20.9% at 72 weeks for Zepbound; COR-I reported −6.1% at 56 weeks for Contrave at full dose. The cost runs the other way — about $99 a month through Currax against $349–$499 through LillyDirect. Contrave is oral, cheap, and frequently the step-therapy hurdle standing in front of the drug you asked for, which is the practical reason to understand what it does before dismissing it.
Full Contrave vs Zepbound comparison →Another oral combination outside the GLP-1 class, no needle involved
Qsymia combines two mechanisms in a single capsule.
About −20.9% at 72 weeks for Zepbound in SURMOUNT-1 against roughly −10.9% at 56 weeks for Qsymia in EQUIP, or −9.8% in CONQUER. Zepbound is $349–$499 through LillyDirect; Qsymia is $100–$200, and generic phentermine plus topiramate around $50. Half the effect for a fifth of the price is a real trade rather than a joke — and for someone paying cash indefinitely, it is the trade the arithmetic often favors.
Full Qsymia vs Zepbound comparison →Compare compounded Tirzepatide providers
Compounded tirzepatide sits at a middle figure of $250/month across 490 price points in the register, spanning $69 to $1,400. The partners below are ordered by our partner economics.
Compare compounded Semaglutide providers
Compounded semaglutide sits at a middle figure of $189/month across 552 price points in the register, spanning $59 to $1,400. The partners below are ordered by our partner economics.
Compare every Zepbound provider
Current price, verification status, product form and the states each seller ships to, all on one screen.